Aurinia Pharmaceuticals (AUPH) Revenue (2019 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Revenue came in at $77.7 million in Q1 2026, up 24.4% YoY from $62.5 million in Q1 2025, and up 0.77% on a QoQ basis from $77.1 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Revenue (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 8 years of Revenue data on file, last reported at $77.7 million in Q1 2026.
- Quarterly Revenue rose 24.4% year-over-year to $77.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.3 million (up 20.62% YoY) and the FY2025 annual result came in at $283.1 million, up 20.38% from the prior year.
- Revenue rose to $77.7 million in Q1 2026, from $77.1 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $77.7 million in Q1 2026 to a low of $21.6 million in Q1 2022.
- A 5-year average of $53.3 million and a median of $55.8 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue surged 2265.97% — and 2023, when it retreated 2.27%.
- Tracing AUPH's Revenue over 5 years: stood at $28.4 million in 2022, then soared by 58.59% to $45.1 million in 2023, then soared by 32.76% to $59.9 million in 2024, then grew by 28.81% to $77.1 million in 2025, then gained by 0.77% to $77.7 million in 2026.
- The last three Revenue figures came in at $77.7 million (Q1 2026), $77.1 million (Q4 2025), and $73.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 83.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.22 Mn |
| Mar 31, 2026 | 77.71 Mn |
| Dec 31, 2025 | 77.11 Mn |
| Sep 30, 2025 | 73.47 Mn |
| Jun 30, 2025 | 70.01 Mn |
| Mar 31, 2025 | 62.47 Mn |
| Dec 31, 2024 | 59.87 Mn |
| Sep 30, 2024 | 67.77 Mn |
| Jun 30, 2024 | 57.19 Mn |
| Mar 31, 2024 | 50.30 Mn |
| Dec 31, 2023 | 45.10 Mn |
| Sep 30, 2023 | 54.52 Mn |
| Jun 30, 2023 | 41.49 Mn |
| Mar 31, 2023 | 34.41 Mn |
| Dec 31, 2022 | 28.44 Mn |
| Sep 30, 2022 | 55.78 Mn |
| Jun 30, 2022 | 28.19 Mn |
| Mar 31, 2022 | 21.63 Mn |
| Dec 31, 2021 | 23.40 Mn |
| Sep 30, 2021 | 14.67 Mn |